Skip to main content
OpenTrials
Completed

NCT Number: NCT05204342

Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France

Evaluation of the following prognostic factors in France, based on national quotation data: volume per center, patient age, geographic distance from a clinical center, delay for chemotherapy,Upfront surgery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Uhmontpellier

Montpellier, 34295, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Diagnosic of Ovarian or Tubal Cancer C56 et C570
  • +/-
  • Carcinose péritonéale C786
  • Tumueur maligne secondaire de la plèvre C782,
  • Tumueur maligne secondaire des ganglions C770 à C779,
  • Tumueur maligne secondaire du foie C787,
  • Tumueur maligne secondaire du péritoine C786

Exclusion criteria

  • autres causes de :
  • Carcinose péritonéale C786
  • Tumueur maligne secondaire de la plèvre C782,
  • Tumueur maligne secondaire des ganglions C770 à C779,
  • Tumueur maligne secondaire du foie C787,
  • Tumueur maligne secondaire du péritoine C786

Treatment and study plan

Primary outcomes

  1. To study the prognostic effect of the volume of activity

    Time frame: at 5 years

    To study the prognostic effect of the volume of activity per center on the risk of recurrence

  2. Verify that the therapeutic sequence

    Time frame: at 5 years

    Verify that the therapeutic sequence of primary surgery and secondary chemotherapy is a good prognostic factor for overall and specific survival at 5 years

Secondary outcomes

  1. Verify that delay in initiation of chemotherapy beyond 4 weeks

    Time frame: at 5 years

    Verify that delay in initiation of chemotherapy beyond 4 weeks after surgery is a poor prognostic element on overall and specific survival at 5 years

  2. Verify that age is a poor prognostic element

    Time frame: at 5 years

    Verify that age is a poor prognostic element for overall and specific survival at 5 years

  3. Verify that geographic distance

    Time frame: at 5 years

    Verify that geographic distance from a clinical center is a poor prognostic element for overall and specific survival at 5 years

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France: Surgical Thresholds, Geographical Distance, Age and Therapeutic Sequence

Acronym: Pro-TOCa

Important dates

Study start
2012
Primary completion
2021
Study completion
2021
First posted
Jan 24, 2022
Registry last updated
Jan 24, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.